Evidence map›Paper›PMID 35664230›Full record

ArticleComputational and structural biotechnology journal2022

Towards discovery of inhibitors of the undecaprenyl-pyrophosphate phosphatase BacA by virtual high-throughput screening.

Marko Jukič, Rodolphe Auger, Victor Folcher, Matic Proj, Hélène Barreteau, Stanislav Gobec, Thierry Touzé

Open access · goldAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. ThemBio · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marko JukičUniversity of Maribor, Faculty of Chemistry and Chemical Engineering, Laboratory of Physical Chemistry and Chemical Thermodynamics, Smetanova 17, Maribor SI-2000, Slovenia.
Rodolphe AugerUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette FR-91198, France.
Victor FolcherUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette FR-91198, France.
Matic ProjUniverza v Ljubljani, Fakulteta za Farmacijo, Aškerčeva cesta 7, Ljubljana SI-1000, Slovenia.
Hélène BarreteauUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette FR-91198, France.
Stanislav GobecUniverza v Ljubljani, Fakulteta za Farmacijo, Aškerčeva cesta 7, Ljubljana SI-1000, Slovenia.
Thierry TouzéUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette FR-91198, France.
Centre National de la Recherche Scientifique · FRUniversity of Ljubljana · SIUniversity of Primorska · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing resistance to common antibiotics is becoming a major challenge that requires the development of new antibacterial agents. Peptidoglycan is an essential heteropolymer of the bacterial envelope that ensures the integrity and shape of all bacteria and is also an important target for antibiotics. The biosynthesis of peptidoglycan depends on a lipid carrier, undecaprenyl phosphate. As a byproduct of peptidoglycan polymerization, the lipid carrier is released as undecaprenyl pyrophosphate, which must be recycled to allow new polymerization cycles. To this end, it undergoes a dephosphorylation process catalyzed by the membrane phosphatase BacA, which is specific and highly conserved in bacteria. In the present study, we identified small molecules displaying inhibitory potency towards BacA. We began by preparing a commercial compound library, followed by high-throughput virtual screening by ensemble docking using the 3D structure of BacA and molecular dynamics snapshots to account for the flexibility of the protein. Of 83 compounds computationally selected and tested in a biochemical assay, one sulfamoylthiophene molecule showed significant inhibition of the undecaprenyl pyrophosphate dephosphorylation activity catalyzed by BacA. Subsequently, an additional 33 scaffold analogs were selected and acquired, of which 6 compounds exhibited BacA inhibition. The IC

Indexed as

Antibacterial drug designAntibacterialsBacABinding site identificationC15-PP, Farnesyl pyrophosphateC55-PP, Undecaprenyl pyrophosphateC55-P, Undecaprenyl phosphateC5-PP, Isopentenyl pyrophosphateEnsemble dockingEscherichia coliGlcNAc, N-acetylglucosamineHTVS, High-Throughput Virtual ScreeningIn silico drug designMD, Molecular DynamicsMIC, Minimum Inhibitory ConcentrationMolecular dynamicsMurNAc, N-acetylmuramic acidNon-covalent inhibitorsPBPs, Penicillin-binding proteinsPG, PeptidoglycanPP, PyrophosphateRA, Residual activityRMSD, Root-mean-square deviationTLC, Thin layer chromatographyUndecaprenyl pyrophosphate phosphataseVirtual screeningVS, Virtual Screening

Identifiers

PMID35664230
PMCPMC9127117
OpenAlexW4280492251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.